REVVITY, INC.
For the period ended Apr 5, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Apr 5, 2026 · Filed May 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Reporting Segment Results of Continuing Operations
Life Sciences
Revenue for the three months ended April 5, 2026 was $361.8 million, as compared to $340.4 million for the three months ended March 30, 2025, an increase of $21.4 million, or 6%, which includes a 2%increase in revenue attributable to acquisitions and divestituresand a 2% increase in revenue attributable to favorable changes in foreign exchange rates. The increase in our Life Sciences segment revenue during the three months ended April 5, 2026 was driven by an increase of $13.5 million in Life Sciences Solutions revenue and an increase of $7.9 million in Software revenue and the extra fiscal week.
Segment operating income for the three months ended April 5, 2026 was $104.0 million, as compared to $105.7 million for the three months ended March 30, 2025, a decrease of $1.7 million, or 2%. Segment operating margin decreased 240 basis points in the three months ended April 5, 2026, as compared to the three months ended March 30, 2025, primarily due to product mix shift, strategic investments in software and new product development and impact of the extra fiscal week.
Diagnostics
Revenue for the three months ended April 5, 2026 was $349.3 million, as compared to $324.4 million for the three months ended March 30, 2025, an increase of $24.9 million, or 8%, which includes a 4% increase in revenue attributable to favorable changes in foreign exchange rates. Theincrease in our Diagnostics segment revenue duringthe three months ended April 5, 2026 was driven by an increase of $20.6 million in Reproductive Health revenue and an increase of $4.3 million in Immunodiagnostics revenue.
Segment operating incomefor the three months ended April 5, 2026 was $76.1 million, as compared to $74.0 millionfor the three months ended March 30, 2025, an increase of $2.1 million, or 3%. Segment operating margin decreased 100 basis points in the three months ended April 5, 2026, as compared to the three months ended March 30, 2025, primarily due to product mix shift, changes in foreign exchange rates, increased tariffs and impact of the extra fiscal week.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.